Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 8/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746499 | 0.91 | HDAC1 (0.41) | BACE1HDAC1HDAC8TP53 | |
| SCHEMBL7879921 | 0.86 | GNRHR (0.43) | HDAC1HDAC8 | |
| SCHEMBL3729395 | 0.81 | CNR2 (0.48) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL17416412 | 0.80 | CNR2 (0.47) | CNR1CNR2 | |
| SCHEMBL3737024 | 0.79 | GNRHR (0.48) | HDAC1HDAC8CNR2 | |
| SCHEMBL3734568 | 0.77 | GRM2 (0.46) | HDAC1HDAC8 | |
| SCHEMBL15415539 | 0.77 | BACE1 (0.47) | TBXA2RBACE1CNR1CNR2 | |
| SCHEMBL31069454 | 0.76 | CNR1 (0.39) | TBXA2RTP53CNR1CNR2 | |
| SCHEMBL31069441 | 0.76 | — | — | |
| SCHEMBL13041699 | 0.74 | CNR2 (0.38) | HDAC1HDAC8CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204375-B1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | REVIRAL LTD (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-10106539-B2 | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) | ReViral Limited (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20170305908-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | ReViral Limited (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3204375-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | Reviral Limited (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055780-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | RE:VIRAL LTD (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305908-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | NR3C2, SAV1, ACE2 | TBXA2R 1490/4885BACE1 2962/4885HDAC1 667/4885 |
| US-10106539-B2 | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) | SPTBN1, NR3C2, SPNS2 | TBXA2R 1499/4885BACE1 2699/4885HDAC1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.